Phenotypic differences in intermediate generalized junctional epidermolysis bullosa with homozygous LAMC2 mutation and a potential genetic modifier

Documenti analoghi

• Sustained clinical remission for 5 years in severe epidermolysis bullosa acquisita following rituximab infusions
  di: Ben Koszegi, et al.
  Pubblicazione: (2024)
• High prevalence of extracutaneous involvement in ITG junctional epidermolysis bullosa
  di: Julie Bonigen, et al.
  Pubblicazione: (2025)
• The future of digital pills and their potential use in dermatological clinical trials
  di: Liana Victory, et al.
  Pubblicazione: (2024)
• Body image disturbance has severe psychosocial impacts in patients suffering from autoimmune blistering diseases
  di: Dedee F. Murrell
  Pubblicazione: (2025)
• A new dawn for orphan diseases in dermatology: The transformative potential of digital twins
  di: Hossein Akbarialiabad, et al.
  Pubblicazione: (2024)